GlassScriptPhysician profile
Gage Patrick Rensch
NPI 1942706650
$11,031.87
in general payments reported to CMS, 2019-2025
34 companies · $2,807 in 2025
The $2,807 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.72 · 2021: $96.12 · 2022: $2,221 · 2023: $2,788 · 2024: $3,101 · 2025: $2,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,458 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,458.03 |
| Education | $238.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,299.36 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $900.26 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $858.35 | 2022-2025 | Tremfya, Remicade, Simponi |
| Genzyme Corporation | $842.07 | 2022-2025 | |
| Lilly USA, LLC | $801.25 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $722.39 | 2021-2025 | Otezla, Enbrel, Otezla |
| Ucb, INC. | $608.74 | 2022-2025 | Bimzelx, Cimzia |
| Convatec INC. | $584.99 | 2024-2025 | |
| Incyte Corporation | $559.95 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $554.91 | 2022-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $551.78 | 2022-2024 | Arazlo, Jublia, Siliq |
| E.R. Squibb & Sons, L.L.C. | $475.87 | 2023-2025 | Sotyktu |
| Pfizer INC. | $324.07 | 2022-2025 | |
| Leo Pharma INC. | $310.48 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $297.86 | 2022-2025 | Nemluvio |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $290.26 | 2023-2025 | |
| Journey Medical Corporation | $167.90 | 2023 | |
| Almirall LLC | $139.57 | 2022-2025 | Seysara |
| Merz North America, INC. | $134.23 | 2022 | |
| Kerecis Limited | $125.24 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Arcutis Biotherapeutics, INC. | $76.85 | 2023-2025 | Zoryve |
| Celgene Corporation | $61.52 | 2023 | Sotyktu |
| Genentech USA, INC. | $43.55 | 2020-2022 | |
| Biofrontera INC. | $39.61 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $33.03 | 2025 | Puraply Wound Matrix |
| Integra Lifesciences Corporation | $32.40 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Helsinn Therapeutics (U.S.), INC. | $31.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.73 | 2022 | |
| Dermavant Sciences, INC. | $30.14 | 2023 | Vtama |
| Mayne Pharma Commercial LLC | $22.62 | 2025 | |
| Therakos LLC | $21.75 | 2025 | Uvadex |
| Mallinckrodt Hospital Products INC. | $21.58 | 2025 | Acthar |
| Krystal Biotech INC | $21.17 | 2025 | Vyjuvek |
| Botanix Sb INC | $14.56 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gage Rensch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.